statnews.com·May 26, 2026
Peyton Greenside, CEO of BigHat Biosciences, emphasizes the limitations of AI in drug development, stating that while AI can rapidly design proteins, the real challenge lies in the lengthy and costly downstream testing required to actually produce new drugs.
Peyton Greenside, CEO of BigHat Biosciences, emphasizes that while AI can rapidly design proteins, the true challenge and resource-intensive aspect of drug development lies in the downstream testing and validation processes. This highlights an investment opportunity in companies focusing on streamlining these downstream processes, as they remain crucial for accelerating AI-driven drug development.